The final, formatted version of the article will be published soon.
REVIEW article
Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1445387
This article is part of the Research Topic Characterization of the Immune Response to Conventional and Advanced Animal Vaccines View all 7 articles
Advancements, Challenges, and Future Perspectives in Developing Feline Herpesvirus 1 as a Vaccine Vector
Provisionally accepted- 1 Chinese Academy of Agricultural Sciences (CAAS), Beijing, China
- 2 Dalian University, Dalian, China
As the most prevalent companion animal, cats are threatened by numerous infectious diseases and carry zoonotic pathogens such as Toxoplasma gondii and Bartonella henselae, which are the primary causes of human toxoplasmosis and cat-scratch disease.Vaccines play a crucial role in preventing and controlling the spread of diseases in both humans and animals. Currently, there are only three core vaccines available to prevent feline panleukopenia, feline herpesvirus, and feline calicivirus infections, with few vaccines available for other significant feline infectious and zoonotic diseases. Feline herpesvirus, a major component of the core vaccine, offers several advantages and a stable genetic manipulation platform, making it an ideal model for vaccine vector development to prevent and control feline infectious diseases. This paper reviews the technologies involved in the research and development of the feline herpesvirus vaccine vector, including homologous recombination, CRISPR/Cas9, and bacterial artificial chromosomes. It also examines the design and effectiveness of expressing antigens of other pathogens using the feline herpesvirus as a vaccine vector. Additionally, the paper analyzes existing technical bottlenecks and challenges, providing an outlook on its application prospects. The aim of this review is to provide a scientific basis for the research and development of feline herpesvirus as a vaccine vector and to offer new ideas for the prevention and control of significant feline infectious and zoonotic diseases.
Keywords: Feline herpesvirus 1, vaccine vector, CRISPR/Cas9, protective immunity, infectious and zoonotic diseases
Received: 07 Jun 2024; Accepted: 27 Aug 2024.
Copyright: © 2024 Tang, Luo, Liang, Lin, Tang, Shaohua, Ding and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xinming Tang, Chinese Academy of Agricultural Sciences (CAAS), Beijing, China
Xinru Luo, Chinese Academy of Agricultural Sciences (CAAS), Beijing, China
Aoxing Tang, Chinese Academy of Agricultural Sciences (CAAS), Beijing, China
Jiabo Ding, Chinese Academy of Agricultural Sciences (CAAS), Beijing, China
Zibin Li, Dalian University, Dalian, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.